HEADER TRANSFERASE 05-JAN-07 2OG8 TITLE CRYSTAL STRUCTURE OF AMINOQUINAZOLINE 36 BOUND TO LCK COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LCK KINASE DOMAIN, RESIDUES 236-498; COMPND 5 SYNONYM: P56-LCK, LYMPHOCYTE CELL-SPECIFIC PROTEIN-TYROSINE KINASE, COMPND 6 LSK, T CELL- SPECIFIC PROTEIN-TYROSINE KINASE; COMPND 7 EC: 2.7.10.2; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: LCK; SOURCE 6 EXPRESSION_SYSTEM: INSECT CELL; SOURCE 7 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS KEYWDS LCK, KINASE DOMAIN, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR X.HUANG REVDAT 3 30-AUG-23 2OG8 1 SEQADV REVDAT 2 24-FEB-09 2OG8 1 VERSN REVDAT 1 27-FEB-07 2OG8 0 JRNL AUTH E.F.DIMAURO,J.NEWCOMB,J.J.NUNES,J.E.BEMIS,C.BOUCHER, JRNL AUTH 2 J.L.BUCHANAN,W.H.BUCKNER,V.J.CEE,L.CHAI,H.L.DEAK, JRNL AUTH 3 L.F.EPSTEIN,T.FAUST,P.GALLANT,S.D.GEUNS-MEYER,A.GORE,Y.GU, JRNL AUTH 4 B.HENKLE,B.L.HODOUS,F.HSIEH,X.HUANG,J.L.KIM,J.H.LEE, JRNL AUTH 5 M.W.MARTIN,C.E.MASSE,D.C.MCGOWAN,D.METZ,K.A.MORGENSTERN, JRNL AUTH 6 A.OLIVEIRA-DOS-SANTOS,V.F.PATEL,D.POWERS,P.E.ROSE, JRNL AUTH 7 S.SCHNEIDER,S.A.TOMLINSON,Y.Y.TUDOR,S.M.TURCI,A.A.WELCHER, JRNL AUTH 8 R.D.WHITE,H.ZHAO,L.ZHU,X.ZHU JRNL TITL DISCOVERY OF AMINOQUINAZOLINES AS POTENT, ORALLY JRNL TITL 2 BIOAVAILABLE INHIBITORS OF LCK: SYNTHESIS, SAR, AND IN VIVO JRNL TITL 3 ANTI-INFLAMMATORY ACTIVITY JRNL REF J.MED.CHEM. V. 49 5671 2006 JRNL REFN ISSN 0022-2623 JRNL PMID 16970394 JRNL DOI 10.1021/JM0605482 REMARK 2 REMARK 2 RESOLUTION. 2.30 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.30 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 NUMBER OF REFLECTIONS : 28465 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.247 REMARK 3 FREE R VALUE : 0.300 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3954 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 82 REMARK 3 SOLVENT ATOMS : 209 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.470 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2OG8 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 10-JAN-07. REMARK 100 THE DEPOSITION ID IS D_1000041096. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IV REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 28695 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.300 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 94.7 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : 0.07700 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 12.2000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.30 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.38 REMARK 200 COMPLETENESS FOR SHELL (%) : 80.9 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.31800 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 3.500 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: PDB ENTRY 1QPC REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54.81 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.72 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 1.0 M LICL, 10-22.5% PEG4000, PH 6.0, REMARK 280 VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 31.34500 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 66.03000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 40.03500 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 66.03000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 31.34500 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 40.03500 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: THE BIOLOGICAL ASSEMBLY IS A MONOMER. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ASP A 236 REMARK 465 ALA A 386 REMARK 465 ARG A 387 REMARK 465 LEU A 388 REMARK 465 ILE A 389 REMARK 465 GLU A 390 REMARK 465 ASP A 391 REMARK 465 ASN A 392 REMARK 465 GLU A 393 REMARK 465 TYR A 394 REMARK 465 THR A 395 REMARK 465 ALA A 396 REMARK 465 ARG A 397 REMARK 465 GLU A 398 REMARK 465 GLY A 399 REMARK 465 ALA A 400 REMARK 465 LYS A 401 REMARK 465 PHE A 402 REMARK 465 ALA A 500 REMARK 465 ARG B 387 REMARK 465 LEU B 388 REMARK 465 ILE B 389 REMARK 465 GLU B 390 REMARK 465 ASP B 391 REMARK 465 ASN B 392 REMARK 465 GLU B 393 REMARK 465 TYR B 394 REMARK 465 THR B 395 REMARK 465 ALA B 396 REMARK 465 ARG B 397 REMARK 465 GLU B 398 REMARK 465 GLY B 399 REMARK 465 ALA B 400 REMARK 465 LYS B 401 REMARK 465 PHE B 402 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLN A 298 CG CD OE1 NE2 REMARK 470 LYS A 335 CG CD CE NZ REMARK 470 LEU A 376 CG CD1 CD2 REMARK 470 ARG A 438 CG CD NE CZ NH1 NH2 REMARK 470 PRO A 447 CG CD REMARK 470 GLN A 451 CG CD OE1 NE2 REMARK 470 GLU A 468 CG CD OE1 OE2 REMARK 470 GLN B 255 CG CD OE1 NE2 REMARK 470 GLN B 309 CG CD OE1 NE2 REMARK 470 PRO B 447 CG CD REMARK 470 GLU B 448 CG CD OE1 OE2 REMARK 470 GLU B 454 CG CD OE1 OE2 REMARK 470 GLU B 468 CG CD OE1 OE2 REMARK 470 THR B 499 OG1 CG2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ARG A 363 -17.02 77.30 REMARK 500 ASP A 364 45.26 -143.76 REMARK 500 GLU B 237 42.20 -85.03 REMARK 500 VAL B 248 -63.21 -102.43 REMARK 500 GLN B 277 144.73 -36.88 REMARK 500 ARG B 363 -12.04 72.78 REMARK 500 ASP B 364 57.83 -152.12 REMARK 500 LEU B 385 -95.72 -101.47 REMARK 500 LYS B 405 -21.79 -36.14 REMARK 500 PRO B 442 104.91 -54.09 REMARK 500 MET B 459 156.88 -48.48 REMARK 500 ASN B 464 -11.71 68.94 REMARK 500 THR B 499 -120.37 -80.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 615 REMARK 615 ZERO OCCUPANCY ATOM REMARK 615 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 615 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 615 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 615 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 615 M RES C SSEQI REMARK 615 HOH A 551 REMARK 615 HOH A 565 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2OFV RELATED DB: PDB REMARK 900 DISCOVERY OF AMINOQUINAZOLINES AS POTENT, ORALLY BIOAVAILABLE REMARK 900 INHIBITORS OF LCK: SYNTHESIS, SAR, AND IN VIVO ANTI-INFLAMMATORY REMARK 900 ACTIVITY DBREF 2OG8 A 237 499 UNP P06239 LCK_HUMAN 236 498 DBREF 2OG8 B 237 499 UNP P06239 LCK_HUMAN 236 498 SEQADV 2OG8 ASP A 236 UNP P06239 CLONING ARTIFACT SEQADV 2OG8 ALA A 500 UNP P06239 CLONING ARTIFACT SEQADV 2OG8 ASP B 236 UNP P06239 CLONING ARTIFACT SEQADV 2OG8 ALA B 500 UNP P06239 CLONING ARTIFACT SEQRES 1 A 265 ASP GLU TRP GLU VAL PRO ARG GLU THR LEU LYS LEU VAL SEQRES 2 A 265 GLU ARG LEU GLY ALA GLY GLN PHE GLY GLU VAL TRP MET SEQRES 3 A 265 GLY TYR TYR ASN GLY HIS THR LYS VAL ALA VAL LYS SER SEQRES 4 A 265 LEU LYS GLN GLY SER MET SER PRO ASP ALA PHE LEU ALA SEQRES 5 A 265 GLU ALA ASN LEU MET LYS GLN LEU GLN HIS GLN ARG LEU SEQRES 6 A 265 VAL ARG LEU TYR ALA VAL VAL THR GLN GLU PRO ILE TYR SEQRES 7 A 265 ILE ILE THR GLU TYR MET GLU ASN GLY SER LEU VAL ASP SEQRES 8 A 265 PHE LEU LYS THR PRO SER GLY ILE LYS LEU THR ILE ASN SEQRES 9 A 265 LYS LEU LEU ASP MET ALA ALA GLN ILE ALA GLU GLY MET SEQRES 10 A 265 ALA PHE ILE GLU GLU ARG ASN TYR ILE HIS ARG ASP LEU SEQRES 11 A 265 ARG ALA ALA ASN ILE LEU VAL SER ASP THR LEU SER CYS SEQRES 12 A 265 LYS ILE ALA ASP PHE GLY LEU ALA ARG LEU ILE GLU ASP SEQRES 13 A 265 ASN GLU TYR THR ALA ARG GLU GLY ALA LYS PHE PRO ILE SEQRES 14 A 265 LYS TRP THR ALA PRO GLU ALA ILE ASN TYR GLY THR PHE SEQRES 15 A 265 THR ILE LYS SER ASP VAL TRP SER PHE GLY ILE LEU LEU SEQRES 16 A 265 THR GLU ILE VAL THR HIS GLY ARG ILE PRO TYR PRO GLY SEQRES 17 A 265 MET THR ASN PRO GLU VAL ILE GLN ASN LEU GLU ARG GLY SEQRES 18 A 265 TYR ARG MET VAL ARG PRO ASP ASN CYS PRO GLU GLU LEU SEQRES 19 A 265 TYR GLN LEU MET ARG LEU CYS TRP LYS GLU ARG PRO GLU SEQRES 20 A 265 ASP ARG PRO THR PHE ASP TYR LEU ARG SER VAL LEU GLU SEQRES 21 A 265 ASP PHE PHE THR ALA SEQRES 1 B 265 ASP GLU TRP GLU VAL PRO ARG GLU THR LEU LYS LEU VAL SEQRES 2 B 265 GLU ARG LEU GLY ALA GLY GLN PHE GLY GLU VAL TRP MET SEQRES 3 B 265 GLY TYR TYR ASN GLY HIS THR LYS VAL ALA VAL LYS SER SEQRES 4 B 265 LEU LYS GLN GLY SER MET SER PRO ASP ALA PHE LEU ALA SEQRES 5 B 265 GLU ALA ASN LEU MET LYS GLN LEU GLN HIS GLN ARG LEU SEQRES 6 B 265 VAL ARG LEU TYR ALA VAL VAL THR GLN GLU PRO ILE TYR SEQRES 7 B 265 ILE ILE THR GLU TYR MET GLU ASN GLY SER LEU VAL ASP SEQRES 8 B 265 PHE LEU LYS THR PRO SER GLY ILE LYS LEU THR ILE ASN SEQRES 9 B 265 LYS LEU LEU ASP MET ALA ALA GLN ILE ALA GLU GLY MET SEQRES 10 B 265 ALA PHE ILE GLU GLU ARG ASN TYR ILE HIS ARG ASP LEU SEQRES 11 B 265 ARG ALA ALA ASN ILE LEU VAL SER ASP THR LEU SER CYS SEQRES 12 B 265 LYS ILE ALA ASP PHE GLY LEU ALA ARG LEU ILE GLU ASP SEQRES 13 B 265 ASN GLU TYR THR ALA ARG GLU GLY ALA LYS PHE PRO ILE SEQRES 14 B 265 LYS TRP THR ALA PRO GLU ALA ILE ASN TYR GLY THR PHE SEQRES 15 B 265 THR ILE LYS SER ASP VAL TRP SER PHE GLY ILE LEU LEU SEQRES 16 B 265 THR GLU ILE VAL THR HIS GLY ARG ILE PRO TYR PRO GLY SEQRES 17 B 265 MET THR ASN PRO GLU VAL ILE GLN ASN LEU GLU ARG GLY SEQRES 18 B 265 TYR ARG MET VAL ARG PRO ASP ASN CYS PRO GLU GLU LEU SEQRES 19 B 265 TYR GLN LEU MET ARG LEU CYS TRP LYS GLU ARG PRO GLU SEQRES 20 B 265 ASP ARG PRO THR PHE ASP TYR LEU ARG SER VAL LEU GLU SEQRES 21 B 265 ASP PHE PHE THR ALA HET 1N8 A 501 41 HET 1N8 B 502 41 HETNAM 1N8 N-{2-[(N,N-DIETHYLGLYCYL)AMINO]-5-(TRIFLUOROMETHYL) HETNAM 2 1N8 PHENYL}-4-METHYL-3-[2-(METHYLAMINO)QUINAZOLIN-6- HETNAM 3 1N8 YL]BENZAMIDE HETSYN 1N8 AMINOQUINAZOLINE 36 FORMUL 3 1N8 2(C30 H31 F3 N6 O2) FORMUL 5 HOH *209(H2 O) HELIX 1 1 PRO A 241 GLU A 243 5 3 HELIX 2 2 SER A 281 LEU A 295 1 15 HELIX 3 3 SER A 323 LYS A 329 1 7 HELIX 4 4 THR A 330 LYS A 335 1 6 HELIX 5 5 THR A 337 ARG A 358 1 22 HELIX 6 6 ARG A 366 ALA A 368 5 3 HELIX 7 7 ALA A 408 GLY A 415 1 8 HELIX 8 8 THR A 418 THR A 435 1 18 HELIX 9 9 THR A 445 GLU A 454 1 10 HELIX 10 10 PRO A 466 TRP A 477 1 12 HELIX 11 11 ARG A 480 ARG A 484 5 5 HELIX 12 12 THR A 486 ASP A 496 1 11 HELIX 13 13 PRO B 241 GLU B 243 5 3 HELIX 14 14 SER B 281 LEU B 286 1 6 HELIX 15 15 LEU B 286 GLN B 294 1 9 HELIX 16 16 SER B 323 LEU B 328 1 6 HELIX 17 17 SER B 332 LEU B 336 5 5 HELIX 18 18 THR B 337 ARG B 358 1 22 HELIX 19 19 ARG B 366 ALA B 368 5 3 HELIX 20 20 ALA B 408 TYR B 414 1 7 HELIX 21 21 THR B 418 THR B 435 1 18 HELIX 22 22 THR B 445 ARG B 455 1 11 HELIX 23 23 PRO B 466 TRP B 477 1 12 HELIX 24 24 ARG B 480 ARG B 484 5 5 HELIX 25 25 THR B 486 ASP B 496 1 11 SHEET 1 A 5 LEU A 245 GLY A 254 0 SHEET 2 A 5 GLY A 257 TYR A 264 -1 O MET A 261 N GLU A 249 SHEET 3 A 5 THR A 268 LEU A 275 -1 O VAL A 270 N GLY A 262 SHEET 4 A 5 TYR A 313 GLU A 317 -1 O ILE A 314 N LYS A 273 SHEET 5 A 5 LEU A 303 VAL A 307 -1 N TYR A 304 O ILE A 315 SHEET 1 B 2 ILE A 370 VAL A 372 0 SHEET 2 B 2 CYS A 378 ILE A 380 -1 O LYS A 379 N LEU A 371 SHEET 1 C 5 LEU B 245 ALA B 253 0 SHEET 2 C 5 GLY B 257 TYR B 264 -1 O VAL B 259 N LEU B 251 SHEET 3 C 5 THR B 268 LEU B 275 -1 O VAL B 272 N TRP B 260 SHEET 4 C 5 TYR B 313 GLU B 317 -1 O ILE B 314 N LYS B 273 SHEET 5 C 5 LEU B 303 VAL B 307 -1 N ALA B 305 O ILE B 315 SHEET 1 D 2 ILE B 370 VAL B 372 0 SHEET 2 D 2 CYS B 378 ILE B 380 -1 O LYS B 379 N LEU B 371 CISPEP 1 GLU A 310 PRO A 311 0 0.98 CISPEP 2 GLU B 310 PRO B 311 0 -0.83 CRYST1 62.690 80.070 132.060 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.015952 0.000000 0.000000 0.00000 SCALE2 0.000000 0.012489 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007572 0.00000